CONTACT PERSON: Dr. Beatriz Cash
TELEPHONE: +44 (0) 1224 272868
Vertebrate Antibodies Limited (VAL) is a spin-out company from the University of Aberdeen. The company co-operates and trades with academic and large industrial organisations. VAL main objective is to advance science by providing high quality monoclonal antibodies (mAbs) to key targets for both research and diagnostic applications across a wide spectrum of species especially to those with an evident shortage of such tools (lower vertebrate research). Antibodies have become the cornerstone of basic research and have found application as laboratory reagents for the detection, quantification and purification of specific proteins, examination of tissue sections and is quickly becoming one of the most effective tools used for disease diagnosis as well as monitoring treatment/vaccines efficacy. By identifying the shortage of antibodies and the future benefits to the Aquaculture industry that can be brought about by providing such products, VAL has invested huge effort to be part of consortiums, collaborations and experienced research groups The antibodies will improve our understanding of fish-parasite interactions, accurate disease diagnosis as well as improving the exiting treatment and vaccination efficacy by providing treatment monitoring tools.
Role in the project:
VAL participation in the project is solely focused in the generation of mAbs towards the most harmful parasites for the European aquaculture industry. The antibodies will provide specific and sensitive diagnostic tools. In addition VAL will be generating antibodies to key immune targets to enhance our understanding of immune-evasion, host invasion, virulence and transmission and evaluate the protection efficacy of the vaccines. VAL will provide contributions in WP1, WP4 and WP8.
Key persons involved:
|Dr. Beatriz Cash is the Chief Technology Officer of VAL. She has a wealth of experience in both academic and industrial domains in mAbs production. Dr. Cash generated the first mAbs at the University of Aberdeen and established the basic protocols used by many other researchers at the University. mAbs produced by Dr. Cash has been successfully commercialised for research as well as for diagnostic and prognostic applications.|